These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 25617196)
1. Hepatitis C drug affordability. Kamal-Yanni M Lancet Glob Health; 2015 Feb; 3(2):e73-4. PubMed ID: 25617196 [No Abstract] [Full Text] [Related]
2. Reducing the price of new hepatitis C drugs in the Tuscany region of Italy. Brunetto MR; De Luca A; Messori A; Zignego AL BMJ; 2015 Jun; 350():h3363. PubMed ID: 26108546 [No Abstract] [Full Text] [Related]
3. Hepatitis C drugs not reaching poor. Callaway E Nature; 2014 Apr; 508(7496):295-6. PubMed ID: 24740042 [No Abstract] [Full Text] [Related]
4. Secrecy on cost of publicly funded hep C treatment. Webster P CMAJ; 2017 Apr; 189(16):E617-E618. PubMed ID: 28438961 [No Abstract] [Full Text] [Related]
5. Dare to refuse the exorbitant price of Sovaldi! Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802 [No Abstract] [Full Text] [Related]
6. Crunching the numbers for viral hepatitis. The Lancet Gastroenterology Hepatology Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):875. PubMed ID: 34626556 [No Abstract] [Full Text] [Related]
7. Market watch: The industry's biggest drug launches. Urquhart L Nat Rev Drug Discov; 2018 Nov; 17(12):855. PubMed ID: 30482955 [No Abstract] [Full Text] [Related]
8. New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US. McCarthy M BMJ; 2015 Apr; 350():h2055. PubMed ID: 25888306 [No Abstract] [Full Text] [Related]
9. [Prescription of new HCV-drugs - what has to be considered judicially]. Mauss S Z Gastroenterol; 2015 Jan; 53(1):43-5. PubMed ID: 25594707 [TBL] [Abstract][Full Text] [Related]
10. Campaigners challenge patent applications for hepatitis C drug in five countries. Bagcchi S BMJ; 2015 Jun; 350():h2938. PubMed ID: 26032985 [No Abstract] [Full Text] [Related]
11. Leaving no one behind: Towards equitable global elimination of hepatitis C. Dahl EH; Zahid H; Aslam K; Jafri W J Glob Health; 2020 Jun; 10(1):010308. PubMed ID: 32257136 [No Abstract] [Full Text] [Related]
12. [Price of new drugs for hepatitis C: Try to understand the incomprehensible]. Bergmann JF Presse Med; 2015 Sep; 44(9):877-80. PubMed ID: 26453430 [No Abstract] [Full Text] [Related]
13. Building a hepatitis C virus treatment strategy to achieve the 2030 vision for Saudi Arabia. Al-Judaibi B Saudi J Gastroenterol; 2017; 23(1):71. PubMed ID: 28139504 [No Abstract] [Full Text] [Related]
14. The new hepatitis C era: the guidelines are now available, reimbursement not yet.. Hullegie SJ; Rijnders BJ Neth J Med; 2014 Oct; 72(8):386-7. PubMed ID: 25387550 [No Abstract] [Full Text] [Related]
15. Access to hepatitis C medicines. Edwards DJ; Coppens DG; Prasad TL; Rook LA; Iyer JK Bull World Health Organ; 2015 Nov; 93(11):799-805. PubMed ID: 26549908 [TBL] [Abstract][Full Text] [Related]
16. [Hepatitis B and hepatitis C, a high stake for public health: how to reconcile health cost control and public health expenses?]. Allerg Immunol (Paris); 1997 Sep; 29(7):215-8. PubMed ID: 9432191 [No Abstract] [Full Text] [Related]
17. Compulsory licences for direct acting antiviral drugs for hepatitis C. Cattaneo A; Maciocco G BMJ; 2016 Oct; 355():i5314. PubMed ID: 27707734 [No Abstract] [Full Text] [Related]
18. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? van de Vooren K; Curto A; Garattini L Eur J Health Econ; 2015 May; 16(4):341-5. PubMed ID: 25407841 [No Abstract] [Full Text] [Related]
19. New hepatitis C therapies: the toolbox, strategies, and challenges. Pawlotsky JM Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495 [TBL] [Abstract][Full Text] [Related]
20. The Treatment of Hepatitis C- An Introduction to the Use of New Medicines. Wörmann B Dtsch Arztebl Int; 2017 Jan; 114(1-02):9-10. PubMed ID: 28143634 [No Abstract] [Full Text] [Related] [Next] [New Search]